Please use this identifier to cite or link to this item:
Title: Eph Receptors in Cancer.
Austin Authors: Arora, Sakshi;Scott, Andrew M ;Janes, Peter W 
Affiliation: Olivia Newton-John Cancer Research Institute
Issue Date: 23-Jan-2023
Date: 2023
Publication information: Biomedicines 2023
Abstract: Eph receptor tyrosine kinases play critical functions during development, in the formation of tissue and organ borders, and the vascular and neural systems. Uniquely among tyrosine kinases, their activities are controlled by binding to membrane-bound ligands, called ephrins. Ephs and ephrins generally have a low expression in adults, functioning mainly in tissue homeostasis and plasticity, but are often overexpressed in cancers, where they are especially associated with undifferentiated or progenitor cells, and with tumour development, vasculature, and invasion. Mutations in Eph receptors also occur in various tumour types and are suspected to promote tumourigenesis. Ephs and ephrins have the capacity to operate as both tumour promoters and tumour suppressors, depending on the circumstances. They have been demonstrated to impact tumour cell proliferation, migration, and invasion in vitro, as well as tumour development, angiogenesis, and metastases in vivo, making them potential therapeutic targets. However, successful development of therapies will require detailed understanding of the opposing roles of Ephs in various cancers. In this review, we discuss the variations in Eph expression and functions in a variety of malignancies. We also describe the multiple strategies that are currently available to target them in tumours, including preclinical and clinical development.
DOI: 10.3390/biomedicines11020315
ORCID: 0000-0002-1296-9447
Journal: Biomedicines
PubMed URL: 36830852
Type: Journal Article
Subjects: Eph receptor
cancer biology
receptor tyrosine kinase
targeted therapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.